Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: J Cell Physiol. 2017 May 3;233(3):2067–2074. doi: 10.1002/jcp.25901

Figure 2.

Figure 2

Fibrotic array gene expression in fibroblasts derived from the SSCT in CTS patients treated with PDGFR inhibitor (AG1296) and VEGRF inhibitor (Axitinib). Significant (p < 0.05) 2-fold changes of fibrotic gene expression of TGF-β1 + AG1296 (Fig. A) and TGF-β1 + Axitinib (Fig. B) in CTS fibroblast compared to vehicle control with TGF-β1. All data are reported as up-regulated more than 2-fold or down-regulated less than 0.5-fold significant regulation, mean ± SE. n=5.